Evolution of SARS-CoV-2: BA.4/BA.5 Variants Continues to Pose New Challenges

被引:7
|
作者
Quadir, Neha [1 ]
Singh, Jasdeep [2 ]
Alam, Anwar [2 ]
Malik, Asrar Ahmad [3 ]
Rahman, Syed Asad [4 ]
Hira, Subhash [5 ]
Ehtesham, Nasreen Zafar [1 ]
Sundar, Durai [2 ]
Hasnain, Seyed Ehtesham [2 ,3 ]
机构
[1] ICMR Natl Inst Pathol, Safdarjung Hosp Campus, New Delhi 110029, India
[2] Indian Inst Technol Delhi, Dept Biochem Engn & Biotechnol, New Delhi 110029, India
[3] Sharda Univ, Sch Basic Sci & Res, Dept Life Sci, Greater Noida 201310, India
[4] BioInception Pvt Ltd, Swift House Ground Floor,18 Hoffmanns Way, Chelmsford CM1, Essex, England
[5] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
来源
VIRUSES-BASEL | 2022年 / 14卷 / 12期
关键词
SARS-CoV-2; BA.4/BA.5; L452R; F486V; COVID-19;
D O I
10.3390/v14122610
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The acquisition of a high number of mutations, notably, the gain of two mutations L452R and F486V in RBD, and the ability to evade vaccine/natural infection-induced immunity suggests that Omicron is continuing to use "immune-escape potential " as an evolutionary space to maintain a selection advantage within the population. Despite the low hospitalizations and lower death rate, the surges by these variants may offset public health measures and disrupt health care facilities as seen recently in Portugal and the USA. Interestingly these BA.4/BA.5 variants have been found to be more severe than the earlier-emerged Omicron variants. We believe that aggressive COVID-19 surveillance using affordable testing strategies might actually help understand the evolution and transmission pattern of new variants. The sudden dip in reporting of new cases in some of the low- and middle-income countries is an alarming situation and needs to be addressed as this could lead to undetected transmission of future variants of interest/concern of SARS-CoV-2 in large population settings, including advent of a 'super' virus. It would be interesting to examine the possible role/influence, if any, of the two different kinds of vaccines, the spike protein-based versus the inactivated whole virus, in the evolution of BA.4/BA.5.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
    Joseph A. Lewnard
    Vennis Hong
    Jeniffer S. Kim
    Sally F. Shaw
    Bruno Lewin
    Harpreet Takhar
    Sara Y. Tartof
    Nature Communications, 14
  • [22] Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
    Qu, Panke
    Faraone, Julia N.
    Evans, John P.
    Zheng, Yi-Min
    Yu, Lianbo
    Ma, Qin
    Carlin, Claire
    Lozanski, Gerard
    Saif, Linda J.
    Oltz, Eugene M.
    Gumina, Richard J.
    Liu, Shan-Lu
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (14): : 1329 - 1331
  • [23] Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
    Wong, Carlos K. H.
    Lau, Kristy T. K.
    Leung, Gabriel M.
    LANCET INFECTIOUS DISEASES, 2023, 23 (06): : 639 - 640
  • [24] Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
    Lewnard, Joseph A.
    Hong, Vennis
    Kim, Jeniffer S.
    Shaw, Sally F.
    Lewin, Bruno
    Takhar, Harpreet
    Tartof, Sara Y.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [25] A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
    Chen, Zhe
    Feng, Leilei
    Wang, Lei
    Zhang, Li
    Zheng, Binyang
    Fu, Hua
    Li, Fengdi
    Liu, Ligai
    Lv, Qi
    Deng, Ran
    Xu, Yanli
    Hu, Yongfeng
    Zheng, Jianhua
    Qin, Chuan
    Bao, Linlin
    Wang, Xiangxi
    Jin, Qi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [26] Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients
    Peled, Yael
    Afek, Arnon
    Patel, Jignesh K.
    Raanani, Ehud
    Segev, Amit
    Ram, Eilon
    Fardman, Alexander
    Beigel, Roy
    Atari, Nofar
    Kliker, Limor
    Abd Elkader, Bayan
    Mandelboim, Michal
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (08): : 1054 - 1058
  • [27] BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
    Tartof, Sara Y.
    Slezak, Jeff M.
    Puzniak, Laura
    Hong, Vennis
    Frankland, Timothy B.
    Ackerson, Bradley K.
    Takhar, Harpreet
    Ogun, Oluwaseye A.
    Simmons, Sarah
    Zamparo, Joann M.
    Jodar, Luis
    McLaughlin, John M.
    LANCET INFECTIOUS DISEASES, 2022, 22 (12): : 1663 - 1665
  • [28] Examination of the affinity of anti-SARS-CoV-2 IgA, which is mucosal immunity, for SARS-CoV-2 BA.4 variant and BA.5 variant
    Hayashi, Takuma
    Hayashi, Takuma
    Yaegashi, Nobuo
    Konishi, Ikuo
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (03) : S526 - S527
  • [29] Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa
    Wolter, Nicole
    Jassat, Waasila
    Walaza, Sibongile
    Welch, Richard
    Moultrie, Harry
    Groome, Michelle J.
    Amoako, Daniel Gyamfi
    Everatt, Josie
    Bhiman, Jinal N.
    Scheepers, Cathrine
    Tebeila, Naume
    Chiwandire, Nicola
    du Plessis, Mignon
    Govender, Nevashan
    Ismail, Arshad
    Glass, Allison
    Mlisana, Koleka
    Stevens, Wendy
    Treurnicht, Florette K.
    Subramoney, Kathleen
    Makatini, Zinhle
    Hsiao, Nei-yuan
    Parboosing, Raveen
    Wadula, Jeannette
    Hussey, Hannah
    Davies, Mary-Ann
    Boulle, Andrew
    von Gottberg, Anne
    Cohen, Cheryl
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [30] The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
    Tartof, Sara Y.
    Slezak, Jeff M.
    Puzniak, Laura
    Hong, Vennis
    Frankland, Timothy B.
    Ackerson, Bradley K.
    Takhar, Harpreet
    Ogun, Oluwaseye A.
    Simmons, Sarah
    Zamparo, Joann M.
    Jodar, Luis
    McLaughlin, John M.
    LANCET INFECTIOUS DISEASES, 2022, 22 (12): : 1665 - 1666